Clinical Trial: Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional

Official Title: Randomized Double--‐Blinded, Controlled Trial to Compare the Effectiveness of Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit as Evaluated

Brief Summary: The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.

Detailed Summary:
Sponsor: Mayo Clinic

Current Primary Outcome: Determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression [ Time Frame: Within the first 5 minutes of arrival to recovery room ]

Measure Train of Four by using TOF Watch device


Original Primary Outcome: Residual neuromuscular blockade [ Time Frame: Within the first 5 minutes of arrival to recovery room ]

Determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Mayo Clinic

Dates:
Date Received: March 15, 2016
Date Started: June 2016
Date Completion: December 2017
Last Updated: July 1, 2016
Last Verified: July 2016